These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33074364)

  • 21. [Long-Term Complete Response by CapeOX plus Nivolumab Chemotherapy for Postoperative Recurrence of Gastric Cancer-A Case Report].
    Katsuyama S; Masuzawa T; Sugimura K; Yanagisawa K; Shinke G; Kinoshita M; Ikeshima R; Hiraki M; Ohmura Y; Hata T; Takeda Y; Murata K
    Gan To Kagaku Ryoho; 2024 Mar; 51(3):326-328. PubMed ID: 38494820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful management of multiple liver metastasis from gastric cancer with second conversion surgery: A case report.
    Sato S; Tanabe K; Ota H; Saeki Y; Ohdan H
    Int J Surg Case Rep; 2023 Jun; 107():108340. PubMed ID: 37216732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report.
    Fukuda K; Arigami T; Tokuda K; Yanagita S; Matsushita D; Kawasaki Y; Iino S; Sasaki K; Nakajo A; Kirishima M; Tanimoto A; Tsubouchi H; Kurahara H; Ohtsuka T
    Surg Case Rep; 2022 Apr; 8(1):58. PubMed ID: 35362899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Advanced Gastric Cancer with Tumor Shrinkage Persisting after the Discontinuation of Nivolumab-A Case Report].
    Sato I; Nakaya N; Obara Y; Ueno S; Nakajima H
    Gan To Kagaku Ryoho; 2020 Dec; 47(12):1715-1717. PubMed ID: 33342990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary malignant melanoma of the esophagus successfully treated with nivolumab: a case report.
    Ito S; Tachimori Y; Terado Y; Sakon R; Narita K; Goto M
    J Med Case Rep; 2021 May; 15(1):237. PubMed ID: 33947459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A case of metastatic gastric cancer showing long-term control with nivolumab after pseudoprogression].
    Okamoto T; Ueda S
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(6):549-554. PubMed ID: 34108354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hyperprogressive Disease during Treatment with Nivolumab for Recurrence of Gastric Cancer].
    Takeoka T; Okada K; Matsuno H; Konishi K; Ota H; Yokoyama S; Fukunaga M; Kobayashi K
    Gan To Kagaku Ryoho; 2020 Jan; 47(1):165-167. PubMed ID: 32381893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Palliative Radiotherapy and Sequential Nivolumab Administration for Recurrent Gastric Cancer-A Case Report].
    Hamakawa T; Nishikawa K; Tanaka E; Nagae A; Toshiyama R; Miyo M; Fujiwara A; Miyake M; Hama N; Miyamoto A; Kato T; Takami K; Hirao M
    Gan To Kagaku Ryoho; 2019 Dec; 46(13):2557-2559. PubMed ID: 32156997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolated adrenocorticotropic hormone deficiency induced by nivolumab treatment for advanced gastric cancer.
    Namikawa T; Shimizu S; Yokota K; Tanioka N; Fukudome I; Munekage M; Uemura S; Maeda H; Kitagawa H; Hanazaki K
    Clin J Gastroenterol; 2021 Aug; 14(4):988-993. PubMed ID: 33715100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Case of Advanced Gastroesophageal Junction Cancer with Bulky Lymph Node Metastases Treated with Nivolumab.
    Nakamura N; Kinami S; Fujita J; Kaida D; Tomita Y; Miyata T; Fujita H; Ueda N; Takamura H; Kosaka T
    Case Rep Oncol; 2020; 13(2):702-707. PubMed ID: 32774260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
    Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
    BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [A Case of Long-Term Progress Control of Unresectable Progressive Gastric Cancer with Nivolumab Introduced during Effective Duration of Secondary Treatment].
    Eguchi S; Akamaru Y; Wada N; Shimaoka T; Harada S; Ikeshima R; Munakata K; Takiuchi D; Hama N; Ota H; Shibata K
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):2045-2047. PubMed ID: 35045488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Kang YK; Boku N; Satoh T; Ryu MH; Chao Y; Kato K; Chung HC; Chen JS; Muro K; Kang WK; Yeh KH; Yoshikawa T; Oh SC; Bai LY; Tamura T; Lee KW; Hamamoto Y; Kim JG; Chin K; Oh DY; Minashi K; Cho JY; Tsuda M; Chen LT
    Lancet; 2017 Dec; 390(10111):2461-2471. PubMed ID: 28993052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A Case of Multiple Lymph Node Metastases Treated with Nivolumab after an Adrenalectomy for Solitary Adrenal Metastasis of Gastric Cancer after a Gastrectomy].
    Nakai M; Ichisawa A; Yamada T; Kimura T; Yonaiyama S; Jin H; Tokura T; Aoki K; Kawashima H; Toyoki Y; Endo M
    Gan To Kagaku Ryoho; 2019 Dec; 46(13):2434-2436. PubMed ID: 32156956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extended total gastrectomy after nivolumab for unresectable multivisceral invasive gastric cancer.
    Toyota S; Naito H; Motoyoshi S; Nakanishi R; Oki E; Orita H; Korenaga D
    Surg Case Rep; 2020 Nov; 6(1):298. PubMed ID: 33237443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A Case of Recurrent Gastric Cancer with Durable Complete Response after Short-Term Nivolumab Therapy].
    Yamamichi K; Yamada M; Sumiyama F; Yamamoto N; Hashimoto Y; Satake R; Hatta M; Sakaguchi T; Kotsuka M; Tokuhara K; Inoue K; Sekimoto M
    Gan To Kagaku Ryoho; 2021 Dec; 48(13):2052-2054. PubMed ID: 35045490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Case of Advanced Gastric Cancer with Peritoneal Metastasis Treated Successfully with Nivolumab.
    Tazawa H; Suzuki T; Komo T; Kubota H; Tahara S; Sada H; Hadano N; Shimizu W; Ishiyama K; Onoe T; Sudo T; Shimizu Y; Tashiro H
    Case Rep Oncol; 2019; 12(2):523-528. PubMed ID: 31427946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient.
    Yatsuda Y; Hirose S; Ito Y; Onoda T; Sugiyama Y; Nagafuchi M; Suzuki H; Niisato Y; Tange Y; Ikeda T; Yamada T; Yamamoto Y; Ohyama Osawa M; Sakamoto N; Moriwaki T; Mizokami Y
    Intern Med; 2021 Apr; 60(7):1011-1017. PubMed ID: 33162479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Case of Long-Term Survival with Recurrent Liver Metastases from Gastric Cancer Treated with Nivolumab.
    Horiuchi A; Akehi S; Fujiwara Y; Kawaharada S; Anai T
    Case Rep Oncol; 2024; 17(1):438-446. PubMed ID: 38455714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.